Paul Ruff to Cost-Benefit Analysis
This is a "connection" page, showing publications Paul Ruff has written about Cost-Benefit Analysis.
Connection Strength
0,090
-
Cost-effectiveness of adjuvant chemotherapy for high-risk stage II and stage III colon cancer in South Africa. Cancer Med. 2023 07; 12(14):15515-15529.
Score: 0,048
-
Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals. JCO Glob Oncol. 2021 12; 7:1730-1741.
Score: 0,043